Gelteq (GELS) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
12 Jun, 2026Financial performance and metrics
Raised approximately AUD $1,004,889 through May 2023 Convertible Notes with a 12% annual interest rate and maturity in December 2025.
February 2024 Convertible Notes raised about AUD $357,338 at a 6% annual interest rate, maturing December 2025.
May 2024 Convertible Notes raised approximately AUD $1 million at a 6% annual interest rate, maturing December 2025.
In January–March 2025, AUD $822,184 in convertible notes converted to equity at USD $2.14/share; AUD $772,136 in loans redeemed.
February 2025 Convertible Notes raised AUD $580,000 at a 20% annual interest rate, maturing July 2026, convertible at USD $2.00/share.
Use of proceeds and capital allocation
Funds from convertible notes and share issuances used to reduce debt and improve the balance sheet.
January 2025 offer allowed note and loan holders to convert to equity, redeem, or continue to maturity, reducing outstanding debt.
Risk factors and disclosures
Indemnification of directors and officers is limited by Australian law and may not cover certain liabilities or legal costs.
SEC considers indemnification for Securities Act liabilities unenforceable as a matter of public policy.
Latest events from Gelteq
- Innovative gel technology boosts drug absorption and is moving toward commercialization and FDA submission.GELS
Planet MicroCap Las Vegas 202617 Jun 2026 - Early-stage gel delivery innovator with limited revenue, high losses, and IPO-dependent growth.GELS
Registration filing12 Jun 2026 - Licensing-driven gel delivery firm seeks $12M equity to fund growth amid ongoing losses.GELS
Registration filing12 Jun 2026 - Net loss widened to AUD $6.6M in FY2025 despite revenue growth and successful IPO.GELS
Q4 202512 Jun 2026 - Pre-revenue, loss-making gel delivery firm seeks IPO to fund IP, R&D, and scale-up amid high risk.GELS
Registration filing12 Jun 2026 - No FY2024 revenue recognized; net loss AUD $3.5M; $5.2M IPO completed; going concern risk remains.GELS
Q4 202412 Jun 2026 - IPO offers 1.3M shares with 7% underwriter discount and warrants, led by Benchmark.GELS
Registration filing12 Jun 2026